We were delighted to talk to Masanori Terashima about the advantages of robot-assisted gastrectomy for clinical stage T1-2N0-2 gastric cancer patients (Clinical Trial Identifier: UMIN000039825).
The abstract ‘Randomized controlled phase III trial to investigate superiority of robot-assisted gastrectomy over laparoscopic gastrectomy for clinical stage T1-2N0-2 gastric cancer patients: Japan Clinical Oncology Group study JCOG1907 (MONA LISA study)’ (ABSTRACT NUMBER: TPS254) was presented at the virtual ASCO Gastrointestinal Cancers Symposium 2021, 15-17 January, 2021.
Questions
- Could you give us a brief overview of the postoperative complications that may occur after surgery in gastric cancer, and their prognostic significance? (0:14)
- What are the advantages and limitations of laparoscopic gastrectomy compared with open gastrectomy? (0:55)
- Could you tell us a little about robot-assisted gastrectomy and its clinical development to date? (2:02)
- What are the aims and design of the JCOG1907 study? (3:05)
- What does the future hold for robot-assisted surgical procedures in oncology? (3:52)
Disclosures: Masanori Terashima has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ASCO GI 2021 (Virtual).
